Importance Prostate cancer is the most common cancer diagnosis made in men with more
than 160 000 new cases each year in the United States. Although it often has an indolent …

In recent years, several new biomarkers supplementing the role of prostate-specific antigen
(PSA) have become available for men with prostate cancer. Although widely used in an ad …

The decision curve is a graphical summary recently proposed for assessing the potential
clinical impact of risk prediction biomarkers or risk models for recommending treatment or …

Background To reduce overdiagnosis and overtreatment, a test is urgently needed to detect
clinically significant prostate cancer (PCa). Objective To develop a multimodal model …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer
Early Detection provide recommendations for prostate cancer screening in healthy men who …

Prostate cancer (PC) is the most common cancer in men and the second leading cause of
cancer-related death worldwide. Many therapeutic advances over the last two decades have …

Early detection of prostate cancer (PC) is largely carried out using assessment of prostate-
specific antigen (PSA) level; yet it cannot reliably discriminate between benign pathologies …

A major focus in urologic research is the identification of new biomarkers with improved
specificity for clinically-significant prostate cancer. A promising new test based on prostate …

In the United States, prostate cancer (CaP) remains the second leading cause of cancer
deaths in men. CaP is predominantly indolent at diagnosis, with a small fraction (25–30%) …

Several new tests, as discussed in this review, have become available during the last 2
years. Although the intended use of most of these tests is to distinguish PCa from benign …